Department of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, LuZhou, China.
Department of Thyroid Surgery, Affiliated Hospital of Southwest Medical University, LuZhou, China.
Am J Otolaryngol. 2021 Mar-Apr;42(2):102920. doi: 10.1016/j.amjoto.2021.102920. Epub 2021 Jan 9.
Thyroid carcinoma is the most common endocrine tumor, and thyroid papillary carcinoma is the most common form. Although thyroid papillary carcinoma presents a good prognosis, some patients still exhibit recurrence or distant metastasis. miR-1301-3p has been found involved in the occurrence and development of some special tumors. Our study aims to investigate the miR-1301-3p expression in thyroid papillary carcinoma, to explore its biological function, and to provide a potential marker for diagnosis and treatment of thyroid papillary carcinoma.
The tissue samples from 70 patients with PTC (n = 35) and benign tumors (n = 35) were collected respectively. miR-1301-3p expression were detected by qPCR. Diagnostic value of miR-1301-3p was analyzed by ROC curve. CCK-8 assays and flow cytometry were performed to detect the effect of miR-1301-3p on TPC-1 function. PCNA expression of protein was detected by WB.
Compared with the normal group, the expression of miR-1301-3p was obviously decreased in both benign group and PTC group. With the higher T and N grades, the lower expression of miR-1301-3p. ROC curve analysis showed that the diagnostic values of miR-1301-3p for benign tumor and PTC were 0.766 and 0.881, respectively. Vitro experiments showed that miR-1301-3p was decreased in TPC-1 cells, then, upregulated miR-1301-3p blocked the TPC-1 cell cycle in G1/S phase, and inhibited the proliferation. PCNA expression was significantly increased in TPC-1 cells and significantly decreased after upregulation of miR-1301-3p.
The present study showed that the expression of miR-1301-3p in PTC was significantly decreased, which was related to T and N grade. Upregulation of miR-1301-3p could inhibit cell proliferation and cell migration. miR-1301-3p may serve as a potential biomarker for the early diagnosis and treatment of PTC.
甲状腺癌是最常见的内分泌肿瘤，甲状腺乳头状癌是最常见的类型。虽然甲状腺乳头状癌预后良好，但仍有部分患者出现复发或远处转移。miR-1301-3p 已被发现参与了一些特殊肿瘤的发生和发展。本研究旨在探讨甲状腺乳头状癌中 miR-1301-3p 的表达，探索其生物学功能，为甲状腺乳头状癌的诊断和治疗提供潜在标志物。
分别收集 70 例 PTC 患者（n=35）和良性肿瘤患者（n=35）的组织样本，采用 qPCR 检测 miR-1301-3p 的表达，通过 ROC 曲线分析 miR-1301-3p 的诊断价值。采用 CCK-8 实验和流式细胞术检测 miR-1301-3p 对 TPC-1 功能的影响，采用 WB 检测 PCNA 蛋白的表达。
与正常组相比，良性组和 PTC 组 miR-1301-3p 的表达均明显降低。miR-1301-3p 的表达随着 T 分级和 N 分级的升高而降低。ROC 曲线分析显示，miR-1301-3p 对良性肿瘤和 PTC 的诊断价值分别为 0.766 和 0.881。体外实验表明，miR-1301-3p 在 TPC-1 细胞中下调，上调 miR-1301-3p 可阻滞 TPC-1 细胞周期于 G1/S 期，并抑制增殖。TPC-1 细胞中 PCNA 表达明显增加，上调 miR-1301-3p 后表达明显降低。
本研究表明，PTC 中 miR-1301-3p 的表达显著降低，与 T 分级和 N 分级有关。上调 miR-1301-3p 可抑制细胞增殖和细胞迁移。miR-1301-3p 可能作为 PTC 早期诊断和治疗的潜在标志物。
